Report
Jérôme VINERIER
EUR 112.84 For Business Accounts Only

Short term view - GALAPAGOS NV : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement.
The next resistance is at €98.00. Breaking below the support at €79.80 would invalidate the trend.
Underlying
Galapagos NV

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Jérôme VINERIER

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch